Canine mdr1 gene mutation in Japan

Journal of Veterinary Medical Science

Volumn 67, Issue 11, 2005, Pages 1103-1107

  Kawabata, Akiko ^a   Momoi, Yasuyuki ^a   Inoue Murayama, Miho ^b   Iwasaki, Toshiroh ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Canine; Ivermectin; MDR1; Mutation

Indexed keywords

PRIMER DNA; RHODAMINE 123; VERAPAMIL;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DOG; GENE; GENE FREQUENCY; GENETICS; JAPAN; METABOLISM; MISSENSE MUTATION; MONONUCLEAR CELL;

ANIMALS; DNA PRIMERS; DOGS; GENE FREQUENCY; GENES, MDR; JAPAN; LEUKOCYTES, MONONUCLEAR; MUTATION, MISSENSE; RHODAMINE 123; VERAPAMIL;

CANIS FAMILIARIS;

EID: 28744433012     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.67.1103     Document Type: Article

References (35)

1. Arceci, R. J. 1993. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215-2222.
2. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. 1992. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473-476.
3. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Huber, H. and Andreeff, M. 1992. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729-2734.
4. Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Raderer, M., Haberl, I., Andreeff, M. and Huber, H. 1996. Involvement of P-glycoprotein in the transmembrane transport of Interleukin-2 (IL-2), IL-4, and Interferon-γ in normal human T lymphocytes. Blood 88: 1747-1754.
5. Ginn, P. E. 1996. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet. Pathol. 33: 533-541.
6. Gupta, S., Kim, C. H., Tsuruo, T. and Gollapudi, S. 1992. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J. Clin. Immunol. 12: 451-458.
7. Hadrick, M. K., Bunch, S. E. and Kornegay, J. N. 1995. Ivermectin toxicosis in two Australian shepherds. J. Am. Vet. Med. Assoc. 206: 1147-1152.
8. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Jojne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. 2000. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97: 3473-3478.
9. Huet, S., Marie, J.- P., Gualde, N. and Robert, J. 1998. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry 34: 248-256.
10. Hugnet, C., Bentjen,S. A. and Mealey, K. L. 2004. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J. Vet. Pharmacol. Ther. 27: 227-229.
11. Hyde, S. C., Emsley, P., Hartshorn, M. J., Mimmack, M. M., Gileadi, U., Pearce, S. R., Gallagher, M. P., Gill, D. R., Hubbard, R. E. and Higgins, C. F. 1990. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature (Lond.) 346: 312-313.
12. Juliano, R. L. and Ling, V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455: 152-162.
13. Kimchi-Sarfaty, C., Gribar, J. J. and Gottesman, M. 2002. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62: 1-6.
14. Leveille-Webster, C. R. and Arias, I. M. 1995. The biology of the P-glycoproteins. J. Membr. Biol. 143: 89-102.
15. Ludescher, C., Pall, G., Irschick, E. U. and Gastl, G. 1998. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br. J. Haematol. 101: 722-727.
16. Mackenzie, C. D., Geary, T. G. and Gerlach, J. A. 2003. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J. 2 (Suppl. 1): S5.
17. Marie, J.- P., Zittoun, R. and Sikic, B. I. 1991. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592.
18. Mealey, K. L. 2004. A new tool that detects ivermectin and other drug sensitivities in dogs. Vet. Med. 99: 419-426.
19. Mealey, K. L. 2004. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27: 257-264.
20. Mealey, K. L., Northrup, N. C. and Bentjen, S. A. 2003. Increased toxicity of P-glycoprotein substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223: 1453-1455.
21. Mealey, K. L., Bentjen, S. A., Gay, J. M. and Cantor, G. H. 2001. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdrl gene. Pharmacogenetics 11: 727-733.
22. Nakamura, T. 2003. MDR1 genotypes related to Pharmacokinetics and MDR1 expression. Yakugaku Zasshi 123: 773-779 (in Japanese).
23. Neff, M. W., Robertson, K. R., Wong, A. K., Safra, N., Broman, K. W., Slatkin, M., Mealey, K. L. and Pedersen, N. C. 2004. Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc. Natl. Acad. Sci. U.S.A. 101: 11725-11730.
24. Nelson, O. L., Carsten. E., Bentjen, S. A. and Mealey, K. L. 2003. Ivermectin toxicity in an Australian shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in collies. J. Vet. Intern. Med. 17: 354-356.
25. Paul, A. J., Tranquilli, W. J., Seward, R. L., Todd, K. S. and DiPietro, J. A. 1987. Clinical observations in Collies given ivermectin orally. Am. J. Vet. Res. 48: 684-685
26. Pétriz, J. and García-López, J. 1997. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11: 1124-1130.
27. Pulliam, J. D., Seward, R. L., Henry, R. T. and Steinberg, S. A. 1985. Investigating ivermectin toxicity in collies. Vet. Med. 7: 33-40.
28. Roulet, A., Puel, O., Gesta, S., Lepage, J.- F., Drag, M., Soll, M., Alvinerie, M. and Pineau, T. 2003. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460: 85-91.
29. Schinkel, A. J., Wagenaar, E., Mol, C. A. A. M. and van Deemter, L. 1996. P-glycoprotein in the blood-brain barrier of mice influence the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97: 2517-2524.
30. Sartor, L. L., Bentjen, S. A., Trepanier, L. and Mealey, K. L. 2004. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J. Vet. Intern. Med. 18: 117-118.
31. Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kromer, H. K. and Cascorbi, I. 2002. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72: 572-583.
32. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84: 7735-7738.
33. Trambas, C., Wang, Z., Cianfriglia, M. and Woods, G. 2001. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br. J. Haematol. 114: 177-184
34. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972.
35. Yas-Natan, E., Shamir, M., Kleinbart, S. and Aroch, I. 2003. Doramectin toxicity in a collie. Vet. Rec. 153: 718-720.